Assessment of The High risk and unmEt Need in patients with CAD and type 2 diabetes (ATHENA): US healthcare resource use, cost, and burden of illness in a commercially insured population
Eric Wittbrodt, Narinder Bhalla, Karolina Andersson Sundell, Phillip Hunt, Nathan D Wong, Marco Kuster, Carl Mellström, Eric Wittbrodt, Narinder Bhalla, Karolina Andersson Sundell, Phillip Hunt, Nathan D Wong, Marco Kuster, Carl Mellström
Abstract
Aims: THEMIS (NCT01991795) demonstrated cardioprotective benefits of ticagrelor plus acetylsalicylic acid (ASA) compared with placebo plus ASA in patients with type 2 diabetes (T2D), stable coronary artery disease (CAD) and no history of myocardial infarction (MI) or stroke. To complement these findings, we assessed clinical outcomes and healthcare costs in commercially insured US patients similar to those in THEMIS.
Methods: This retrospective, observational study used data from Optum. The T2D-CAD cohort (n = 154,369) included patients (≥50 years old) either with high cardiovascular risk or taking a P2Y12 inhibitor. The THEMIS-like cohort (n = 126,938) comprised patients (≥50 years old) at high cardiovascular risk; the THEMIS-PCI-like cohort comprised a subset of these patients with prior percutaneous coronary intervention (PCI) (n = 18,394).
Results: Mean follow-up was 2.4-2.5 years. Incidence rates of the composite outcome (death, MI, and stroke) were 6.56 (95% CI 6.50-6.63), 6.21 (6.14-6.28), and 5.57 (5.39-5.74) per 100 person-years, and annualized healthcare costs per patient were US$15,848, US$16,044, and US$20,934 for the T2D-CAD, THEMIS-like, and THEMIS-PCI-like cohorts, respectively.
Conclusions: Commercially insured patients similar to those in THEMIS had high cardiovascular event rates and healthcare costs, highlighting a need for improved preventive strategies.
Keywords: Antiplatelet drugs; Cardiovascular disease; Health resources; Percutaneous coronary intervention; Type 2 diabetes.
Conflict of interest statement
Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: E.W., N.B., K.A.S., P.H., M.K., and C.M. are employees of AstraZeneca. N.W. is a consultant for AstraZeneca.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Source: PubMed